cigna semaglutide coverage Expands Its Medicare Advantage Plans for 2023, Giving Americans More Health Care Choices, Personalization and Social Support Press Releases | Cigna Healthcare

Data from a large, randomized clinical trial named SELECT indicated cardiovascular protective benefits from taking the GLP-1 weight loss therapeutic Wegovy for a sub-population with preexisting cardiovascular disease

Particularly, it determined the upregulation of ROS-scavenging enzymes, anti-inflammatory cytokines, (IL-10, IL-6 and PPAR ), tight junctions proteins, such as ZO-1, MUC-2, claudin-3, and the downregulation of inflammatory genes (TNF-, IL-1) [14]

[1] This may change in the future, but as of January 2026, Wegovy is not available through the PAP

A rise in creatinine level up to 30% from baseline is an anticipated finding with drug initiation or dose modification and is due to the reduction in intraglomerular pressure

32.5%) or DPP-4i ( n = 24,370

The app does not interpret why the scale stalled that is a question for your clinician but it gives you a clearer picture to bring to the conversation